New drug combo aims to wipe out breast cancer before surgery

NCT ID NCT02326974

First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 3 times

Summary

This study tests whether giving two targeted drugs (T-DM1 and pertuzumab) before surgery can completely eliminate cancer in women with early-stage HER2-positive breast cancer. About 164 participants with stage II or III disease will receive the combination, then have surgery to check if no cancer remains. The goal is to see if this approach works better for tumors with certain HER2 patterns.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Tennessee Oncology/Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.